As pancreatic cancer approaches the low grade PanIN stage (PanIN 1A and 1B), mutations are acquired in CDKN2A gene in the form of homozygous deletions, mutations, or promoter hyper-methylation[7,37]. This evidence concerns the gene CDKN2A and familial pancreatic carcinoma.